Hsp90 Inhibition Suppresses Mutant EGFR-T790M Signaling and Overcomes Kinase Inhibitor Resistance

The epidermal growth factor receptor (EGFR) secondary kinase domain T790M non–small cell lung cancer (NSCLC) mutation enhances receptor catalytic activity and confers resistance to the reversible tyrosine kinase inhibitors gefitinib and erlotinib. Currently, irreversible inhibitors represent the pri...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Shimamura, Takeshi, Li, Danan, Ji, Hongbin, Haringsma, Henry J., Liniker, Elizabeth, Borgman, Christa L., Lowell, April M., Minami, Yuko, McNamara, Kate, Perera, Samanthi A., Zaghlul, Sara, Thomas, Roman K., Greulich, Heidi, Kobayashi, Susumu, Chirieac, Lucian R., Padera, Robert F., Kubo, Shigeto, Takahashi, Masaya, Tenen, Daniel G., Meyerson, Matthew, Wong, Kwok-Kin, Shapiro, Geoffrey I.
Формат: Artigo
Язык:Inglês
Опубликовано: 2008
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC3272303/
https://ncbi.nlm.nih.gov/pubmed/18632637
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-07-5428
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы